Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation

Fig. 3

PKC inhibition abrogates I3A induced B7-H3 protein expression. a LM7 cells were treated with 22 doses of PDBu and evaluated with the immunofluorescence screen. Total B7-H3 signal per cell (left panel; N = 4) was normalized by averages of DMSO-treated wells. Filled circles represent detection by B7-H3-specific antibody and unfilled circles isotype IgG control. Representative LM7 fluorescent images (right panel) after treatment with indicated concentrations of PDBu are shown. bc Immunofluorescence analysis for the combinational treatment of 8 doses of I3A and 12 doses of sotrastaurin was performed. b B7-H3 signal heatmap and c synergistic score heatmap (ZIP model) are shown. The total B7-H3 signal per cell was normalized by DMSO-treated samples (0 µM Sotrastaurin, 0 µM I3A; 0%) and 0.37 µM I3A with 0 µM Sotrastaurin (100%). Data are shown as means of quadruplicates. Negative synergistic scores indicate antagonistic effects. d Western blot analysis for the combinational treatment of I3A and sotrastaurin. B7-H3 protein expression relative to β-actin normalized by 0 h treated samples (left panel) and representative western blots (middle and right panels) are shown. Data represents mean ± SD (a and d). *p < 0.05, ****p < 0.0001, ns, non-significant by two-way ANOVA (d)

Back to article page